[go: up one dir, main page]

MX2024001179A - Proteinas de union a antigenos que se unen especificamente a ct45. - Google Patents

Proteinas de union a antigenos que se unen especificamente a ct45.

Info

Publication number
MX2024001179A
MX2024001179A MX2024001179A MX2024001179A MX2024001179A MX 2024001179 A MX2024001179 A MX 2024001179A MX 2024001179 A MX2024001179 A MX 2024001179A MX 2024001179 A MX2024001179 A MX 2024001179A MX 2024001179 A MX2024001179 A MX 2024001179A
Authority
MX
Mexico
Prior art keywords
antigen binding
binding proteins
polypeptide
sub
nucleic acids
Prior art date
Application number
MX2024001179A
Other languages
English (en)
Inventor
Sara Yousef
Sebastian Bunk
Claudia Wagner
Dominik Maurer
Felix Unverdorben
Andreas Moritz
Fabian Brunk
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of MX2024001179A publication Critical patent/MX2024001179A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona una proteína de unión a antígenos que se une específicamente a un péptido antigénico de CT45 que está formando un complejo con una proteína del complejo principal de histocompatibilidad (MHC), en donde el péptido antigénico de CT45 comprende o consiste en la secuencia de aminoácidos de SEQ ID NO: 138 (KIFEMLEGV) y en donde la proteína de unión a antígenos comprende un primer polipéptido que comprende un dominio variable VA que comprende las regiones determinantes de la complementariedad CDRa1, CDRa2 y CDRa3 y un segundo polipéptido que comprende un dominio variable VB que comprende las CDRb1, CDRb2 y CDRb3. Además, se proporcionan ácidos nucleicos que codifican las proteínas de unión a antígenos de la invención, vectores que comprenden esos ácidos nucleicos, células recombinantes que expresan las proteínas de unión a antígenos y composiciones farmacéuticas que comprenden las proteínas de unión a antígenos. La invención proporciona, además, las proteínas de unión a antígenos para el uso en medicina y un método para producir la proteína de unión a antígenos.
MX2024001179A 2021-07-27 2022-07-27 Proteinas de union a antigenos que se unen especificamente a ct45. MX2024001179A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163203582P 2021-07-27 2021-07-27
EP21188018 2021-07-27
US202263335399P 2022-04-27 2022-04-27
PCT/EP2022/071104 WO2023006828A1 (en) 2021-07-27 2022-07-27 Antigen binding proteins specifically binding ct45

Publications (1)

Publication Number Publication Date
MX2024001179A true MX2024001179A (es) 2024-02-27

Family

ID=82939905

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001179A MX2024001179A (es) 2021-07-27 2022-07-27 Proteinas de union a antigenos que se unen especificamente a ct45.

Country Status (13)

Country Link
US (2) US12209137B2 (es)
EP (1) EP4377330A1 (es)
JP (1) JP2024529467A (es)
KR (1) KR20240038028A (es)
AU (1) AU2022318257A1 (es)
CA (1) CA3226437A1 (es)
CL (1) CL2024000207A1 (es)
CO (1) CO2024000677A2 (es)
IL (1) IL310374A (es)
MX (1) MX2024001179A (es)
PE (1) PE20240779A1 (es)
TW (1) TW202321277A (es)
WO (1) WO2023006828A1 (es)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
JP3866760B2 (ja) 1993-02-22 2007-01-10 ザ ロックフェラー ユニバーシティ 一過性トランスフェクションによる高力価のヘルパーフリーのレトロウイルスの生産
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
DE69633973T2 (de) 1995-09-11 2005-12-22 Kyowa Hakko Kogyo Co., Ltd. Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
ES2203782T3 (es) 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
EP2287185A3 (en) 1999-12-06 2012-10-10 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
DE10225139A1 (de) 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
US7751825B2 (en) 2002-06-27 2010-07-06 Qualcomm Incorporated Controlling geographic location information of devices operating in wireless communication systems
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
JP2007519910A (ja) 2004-01-28 2007-07-19 イマティクス バイオテクノロジーズ ゲーエムベーハー 腫瘍関連ペプチドの同定および定量方法
US20110177079A1 (en) 2004-09-08 2011-07-21 Ludwig Institute For Cancer Research Cancer-testis antigens
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
US10464987B2 (en) 2009-10-06 2019-11-05 Abbvie Inc. Human single-chain T cell receptors
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
IN2015DN00880A (es) 2012-07-27 2015-06-12 Univ Illinois
CA3108192A1 (en) 2012-12-14 2014-06-19 Biontech Rna Pharmaceuticals Gmbh Novel mhc-independent tumor-associated antigens
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
WO2017195153A1 (en) 2016-05-11 2017-11-16 The University Of Chicago Methods of treating cancers with ct45 targeted therapies
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
CA3069842A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
US20220175899A1 (en) 2019-04-11 2022-06-09 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer

Also Published As

Publication number Publication date
JP2024529467A (ja) 2024-08-06
IL310374A (en) 2024-03-01
US20250122302A1 (en) 2025-04-17
WO2023006828A1 (en) 2023-02-02
AU2022318257A1 (en) 2024-02-08
CO2024000677A2 (es) 2024-05-10
US12209137B2 (en) 2025-01-28
US20230057987A1 (en) 2023-02-23
KR20240038028A (ko) 2024-03-22
EP4377330A1 (en) 2024-06-05
PE20240779A1 (es) 2024-04-17
TW202321277A (zh) 2023-06-01
CA3226437A1 (en) 2023-02-02
CL2024000207A1 (es) 2024-06-14

Similar Documents

Publication Publication Date Title
BR112022001923A2 (pt) Proteína de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica, método de produção da proteína de ligação ao antígeno
DE60332645D1 (de) Ii-key/antigene epitop-hybrid-peptid-vakzine
WO2021198706A3 (en) Coronavirus vaccines
CY1110670T1 (el) Βελτιωση της ομοιογενειας και εκκρισης των ανασυνδυασμενων πρωτεϊνων σε συστηματα θηλαστικων
WO1989006694A1 (en) Process for selection of proteinaceous substances which mimic growth-inducing molecules
CA2289912A1 (en) Human receptor proteins; related reagents and methods
RU2003106809A (ru) Гены гомологичных иммунодоминантных белков ehrlichia canis в 28-килодальтон и их применение
MXPA05013526A (es) Secuencias de acido nucleico que codifican y composiciones que comprenden el peptido de senal de ige y/o il-15 y metodos para uso de los mismos.
EA199800046A1 (ru) Полипептид, последовательность днк, вакцинная композиция (варианты), антитело или его фрагмент, вакцина, применения указанных полипептида, последовательности днк и антитела или его фрагмента
MX2023008351A (es) Heterodimeros de proteinas de membrana tipo i y metodos de uso de los mismos.
MX2023012902A (es) Proteinas de union a antigenos que se unen especificamente a prame.
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
MX2024001179A (es) Proteinas de union a antigenos que se unen especificamente a ct45.
ATE327251T1 (de) Methode zur reduzierung der immunogenizität von staphylokinase durch entfernen von t-zell epitopen
JPWO2020071554A5 (es)
KR960705583A (ko) Mhc 단백질의 원핵세포내 형질발현(prokaryotic expression of mhc proteins)
CN102000329A (zh) 一种改造的非致病细菌来源的鞭毛素粘膜佐剂及制备方法
DE69935599D1 (de) Modifizierte hcv peptid-impfstoffe
Nemoto et al. A disulfide bridge mediated by cysteine 574 is formed in the dimer of the 70-kDa heat shock protein
RU2001117860A (ru) ГЕНЫ ГОМОЛОГИЧНЫХ ИММУНОДОМИНАНТНЫХ БЕЛКОВ МАССОЙ 28-КИЛОДАЛЬТОН Ehrlichia canis И ИХ ПРИМЕНЕНИЕ
WO2003070768A3 (en) Cd40 splice variants,method of detection thereof, compositions comprising said variant(s) or nucleic acid encoding the same and use thereof
WO2022162012A3 (en) Antibodies broadly targeting coronaviruses and uses thereof
Tindall et al. Assessment by sedimentation equilibrium analysis of a heterologous macromolecular interaction in the presence of self-association: interaction of S5 with S8
AR126579A1 (es) Proteínas de unión a antígeno que se unen específicamente a ct45
WO2004056316A3 (en) Vaccines against hiv-1 tat protein to generate neutralizing antibodies